Tirzepatide results are among the strongest weight-loss and glycemic effects seen for a non-surgical therapy. SURMOUNT-1 showed 15 to 20.9 percent mean body weight loss across doses over 72 weeks; SURPASS trials showed A1C reductions of 1.8 to 2.4 percentage points, with majorities reaching the non-diabetic A1C range. Trajectory is front-loaded — roughly half of total weight loss in the first 6 months — with plateau by 18 to 24 months. Real-world results track approximately 70 to 80 percent of trial numbers due to adherence and titration variability.
Weight Loss by Dose: SURMOUNT-1 at 72 Weeks
| Dose | Mean Weight Loss | Reached ≥5% | Reached ≥10% | Reached ≥15% | Reached ≥20% | Reached ≥25% |
|---|---|---|---|---|---|---|
| Placebo | 3.1% | 35% | 16% | 5% | 2% | 0% |
| 5 mg | 15.0% | 85% | 69% | 50% | 30% | 15% |
| 10 mg | 19.5% | 89% | 78% | 64% | 50% | 27% |
| 15 mg | 20.9% | 91% | 83% | 71% | 57% | 36% |
These are means. Individual response varies: some patients lose more than the mean, some less, and about 10 percent of patients respond poorly even at the 15 mg dose.
Weight Loss Trajectory
| Time Point | Typical Cumulative Loss (10 mg) |
|---|---|
| Week 4 | 2–4% |
| Week 12 | 5–7% |
| Week 24 | 10–12% |
| Week 36 | 14–16% |
| Week 52 | 17–18% |
| Week 72 | 19–20% (plateau begins) |
| Week 88 (extension) | Maintained at similar level |
A1C Results: SURPASS Program
| Trial | Comparison | Tirzepatide A1C Drop | % Reaching A1C <5.7 |
|---|---|---|---|
| SURPASS-1 (monotherapy) | Placebo | 1.87–2.07% | 31–52% |
| SURPASS-2 | Semaglutide 1 mg | 2.01–2.30% (vs 1.86% semaglutide) | 29–46% |
| SURPASS-3 | Insulin degludec | 1.93–2.37% | 23–43% |
| SURPASS-4 | Insulin glargine | 2.13–2.58% | 23–48% |
| SURPASS-5 | Placebo (add-on to insulin) | 2.11–2.40% | 15–43% |
| SURMOUNT-2 (patients with T2D) | Placebo | 2.08–2.11% | 48–55% |
Across the program, 70 to 90 percent of patients reached A1C under 7 percent and 15 to 55 percent reached the non-diabetic range of under 5.7 percent. See our A1C levels guide for targets.
Factors That Predict Better Response
- Higher starting BMI
- Female sex (modestly more weight loss in trials)
- Prediabetes or newer type 2 diabetes (shorter duration)
- Able to titrate to 10 or 15 mg (tolerates GI side effects)
- Concurrent lifestyle change (500–750 kcal/day deficit, protein 1.2+ g/kg, resistance training)
- Adequate sleep (6.5 hours or more)
- No interfering medications (glucocorticoids, some antipsychotics)
Real-World vs Trial Results
Retrospective analyses of US prescription databases suggest real-world weight loss is roughly 70 to 80 percent of trial averages, typically:
- 5 mg: about 10 to 12 percent real-world loss at 12 months
- 10 mg: about 13 to 16 percent
- 15 mg: about 15 to 18 percent
Gaps vs trial results usually come from: incomplete titration to labeled max, missed doses, shorter total treatment duration, and less intensive lifestyle coaching.
Side Effect Profile While Achieving Results
- Nausea: 25–30% (worst during titration)
- Diarrhea: 15–20%
- Constipation: 10–15%
- Vomiting: 8–12%
- Decreased appetite: 10–15% (often considered desirable)
- Injection-site reactions: 3–5%
- Hypoglycemia: rare as monotherapy; increased if combined with insulin or sulfonylureas
What Plateau Looks Like
- Weight stabilizes within a 2- to 4-pound range for 6 or more weeks
- Appetite is still controlled but no further loss occurs without new intervention
- A1C stabilizes at its new equilibrium
- Body composition may still be improving (muscle up, fat down) even if the scale is flat
- Continuing the medication at the current dose preserves gains
Maintaining Results Long-Term
SURMOUNT-4 randomized patients at week 36 to continue tirzepatide or switch to placebo. Those who continued maintained loss through week 88; those switched regained 14 percent of body weight on average. The implication: tirzepatide acts more like a maintenance agent than a “cure.” Stopping leads to substantial regain in most patients. Durable metabolic improvement requires continued medication, sustained lifestyle change, or both.
When Results Are Disappointing
- Confirm you are at the intended dose (many patients plateau at 5 mg because titration stopped early)
- Review injection technique and storage
- Audit calorie intake over a 2-week food log
- Add resistance training and protein targeting (1.2 to 1.6 g/kg)
- Check for contributing conditions (untreated sleep apnea, hypothyroidism, elevated cortisol)
- Consider switch to injection Wegovy (semaglutide 2.4 mg), oral semaglutide, or combination with SGLT2 inhibitor if still diabetic
Related Reading
See our guides on treatment, nutrition during GLP-1 therapy, and prediabetes basics.
The Bottom Line
Tirzepatide results in the SURMOUNT and SURPASS trials are among the strongest for a non-surgical therapy — 15 to 21 percent weight loss and 1.8 to 2.4 points of A1C reduction over 52 to 72 weeks. Trajectory is front-loaded, with a plateau at 18 to 24 months. Individual response varies widely, and real-world results track 70 to 80 percent of trial averages. Reaching the full dose (10 or 15 mg), adhering weekly, and pairing with protein-forward nutrition plus resistance training are the main levers to get closer to trial-level results. Once a plateau is reached, continuation maintains gains; stopping generally reverses them within a year.
